Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Study：Clinical Study of Efficacy and Safety of Histamine Human Immunoglobulin (ShuYangMinNing) in the Treatment of Chronic Spontaneous Urticaria (CSU)

NCT06250400 is registered in ClinicalTrials.gov with Hangzhou Grand Biologic Pharmaceutical, Inc. as lead sponsor.

NCT NCT06250400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06250400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Study：Clinical Study of Efficacy and Safety of Histamine Human Immunoglobulin (ShuYangMinNing) in the Treatment of Chronic Spontaneous Urticaria (CSU)
Lead sponsor
Hangzhou Grand Biologic Pharmaceutical, Inc.
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2024
Completion date
December 31, 2025
Enrollment
252 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria